AI Article Synopsis
- IDO is highly expressed in papillary thyroid microcarcinoma (PTMC), which is linked to the activation of regulatory T cells (Treg) and decreased immune response, potentially contributing to tumor progression.
- A study involving 124 PTMC samples found that higher levels of IDO correlated with reduced CD3+ T cells and increased FOXP3+ Treg cells, indicating those tumors have more aggressive characteristics, such as extrathyroidal extension and multifocality.
- The results suggest that IDO expression and Treg infiltration may disrupt the body's immune response against tumors, serving as potential predictive factors for tumor behavior in PTMC patients.
Article Abstract
Background: Indoleamine 2,3-dioxygenase (IDO) is overexpressed in many different types of tumor and is associated with activation of FOXP3+ regulatory T cells (Treg cells) and downregulation of cytotoxic cellular immunity in the tumor microenvironment. It has been suggested that IDO inhibitors can be utilized as an effective therapeutic agent against human cancers. However, the expression of IDO and its association with tumor-infiltrating lymphocytes (TILs) remain unclear in papillary thyroid microcarcinoma (PTMC).
Methods: Immunohistochemical staining for IDO expression was performed on 124 PTMC samples. TIL subsets (CD3+, CD8+, and FOXP3+ T cells) were counted in serial sections. The relationships between the expression of IDO and infiltration of TIL subsets, as well as the relationships between these immunomodulating factors and clinicopathologic parameters of PTMCs, were analyzed.
Results: There was a significant correlation between IDO expression and reduced CD3+ TIL and increased FOXP3+ TIL. IDO expression was found in 31% of PTMC and was associated with aggressive clinicopathologic features of the tumor such as extrathyroidal extension (ETE) and multifocality. High infiltration of FOXP3+ Treg cells in the tumor was associated with lymph node metastasis, ETE, and multifocality. Furthermore, high FOXP3/CD8+ ratio was associated with multifocality and lymph node metastasis, and high FOXP3+/CD3+ ratio was related to ETE and multifocality. In multivariate analyses, IDO expression was found to be an independent predictive factor for ETE and tumor multifocality.
Conclusions: IDO expression and infiltration of FOXP3+ Treg cells were closely related to each other and were associated with aggressive features of PTMC, suggesting that disruption of antitumor immunity by IDO expression, and thus, infiltration of FOXP3+ Treg cells may contribute to tumor progression in PTMC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/thy.2013.0423 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bacillus subtilis-derived-exopolysaccharide halts depigmentation and autoimmunity in vitiligo.
J Invest Dermatol
December 2024
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago (IL), USA; Department of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA. Electronic address:
Vitiligo has a complex multifactorial etiology involving a T-cell mediated autoimmune response to cutaneous melanocytes. Microbial dysbiosis has been assigned a contributing role in vitiligo etiology. Treating vitiligo can be a challenging task and finding novel treatment approaches is crucial.
View Article and Find Full Text PDFPolymorphonuclear myeloid-derived suppressor cells regulates immune recovery during HIV infection through PD-L1 and TGF-β pathways.
Front Cell Infect Microbiol
January 2025
Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.
Background: Although MDSCs are widely recognized for their immunoinhibitory effects in pathological conditions, their function during HIV infection particularly within the mechanisms underlying incomplete immune recovery remains elusive.
Methods: We conducted a cross-sectional study in which 30 healthy controls and 62 HIV-1-infected subjects [31 immunological non-responders (INRs) and 31 immunological responders (IRs)] were selected. The proportion of MDSCs was determined in each category of participants.
RAD001-mediated mTOR targeting in human monocyte-derived dendritic cells shifts them toward an immunogenic phenotype.
Immunol Res
December 2024
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Dendritic cells (DCs) are essential for promoting T lymphocyte responses since they are specialist antigen-presenting cells. In order to maintain tolerance or initiate immune responses, DCs must be activated in a balanced and regulated manner via diverse signaling pathways. By using a variety of pharmacological components, we can interfere with their different signaling pathways such as the mammalian target of rapamycin (mTOR) to appropriately modulate DC activity.
View Article and Find Full Text PDFIndoleamine 2, 3-dioxygenase Regulates the Differentiation of T Lymphocytes to Promote the Growth of Gastric Cancer Cells through the PI3K/Akt/mTOR Pathway.
Cell Biochem Biophys
December 2024
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
To investigate the regulatory mechanism of indoleamine 2, 3-dioxygenase (IDO) in T lymphocyte differentiation and its role in promoting the growth of gastric cancer (GC) cells through the PI3K/Akt/mTOR pathway. GC cell lines (MFC and NCI-N87) and PBMC cells were co-cultured and IDO inhibitor 1-methyl-tryptophan (1-MT) was added. The proliferation was detected by CCK-8, the apoptosis was detected by flow cytometry, and the contents of TNF-α, IL-1β, IL-6, IL-8, and INF-γ were detected by ELISA.
View Article and Find Full Text PDFIncreased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting.
Blood Res
December 2024
Department of Cellular and Molecular Biology, Faculty of Biological Sciences, North Tehran Branch, Azad University, Tehran, Iran.
Purpose: This study aimed to determine the frequency of regulatory T cells (Tregs) (CD4/FOXP3) and indoleamine 2,3-dioxygenase (IDO) expression in patients with acute myeloid leukemia (AML).
Methods: This cross-sectional case-control study was conducted between Jan 2022 and Dec 2023. Bone marrow samples were collected from 20 healthy individuals and 15 patients with AML.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!